What to expect from targeted therapy for acute myeloid leukaemia

Acute myeloid leukaemia cells can have molecular changes that guide treatment selection. The team may use blood or bone marrow testing to look for a target and to understand the leukaemia’s response. A targeted medicine may be used alone, alongside chemotherapy, or as part of a plan leading to a stem cell transplant, depending on the clinical situation.

Some medicines are tablets taken on a schedule; others are given in hospital or clinic. Monitoring can include blood counts, liver and kidney tests, heart checks, infection assessment and bone marrow evaluation. Side effects vary by medicine and may include nausea, diarrhoea, fatigue, rash, liver-test changes or low blood counts.

Take doses exactly as prescribed and ask before crushing tablets or changing the schedule. Tell the team about every medicine, supplement and herbal product because interactions can alter treatment levels. Check your temperature if instructed, practise careful hand hygiene, keep appointments and report symptoms early. Ask for help with food, transport and emotional strain when treatment is intensive.

Contact the leukaemia team urgently for a fever, chills, new cough, breathlessness, severe diarrhoea or vomiting, inability to drink, unusual bleeding, black stools, severe headache or confusion. Seek emergency help for collapse, severe breathing difficulty or uncontrolled bleeding. Do not wait for the next appointment when infection or bleeding is possible.

Ask which target was found, how the medicine is taken, what to do after a missed dose, which interactions matter, how response will be measured, and whether a transplant assessment is part of the plan. Request written instructions for fever, bleeding and after-hours contact.